The
accuracy of structure-based (SB) virtual screening (VS) is
heavily affected by the scoring function used to rank a library of
screened compounds. Even in cases where the docked pose agrees with
the experimental binding mode of the ligand, the limitations of current
scoring functions may lead to sensible inaccuracies in the ability
to discriminate between actives and inactives. In this context, the
combination of SB and ligand-based (LB) molecular similarity may be
a promising strategy to increase the hit rates in VS. This study explores
different strategies that aim to exploit the synergy between LB and
SB methods in order to mitigate the limitations of these techniques,
and to enhance the performance of VS studies by means of a balanced
combination between docking scores and three-dimensional (3D) similarity.
Particularly, attention is focused to the use of measurements of molecular
similarity with PharmScreen, which exploits the 3D distribution of
atomic lipophilicity determined from quantum mechanical-based continuum
solvation calculations performed with the MST model, in conjunction
with three docking programs: Glide, rDock, and GOLD. Different strategies
have been explored to combine the information provided by docking
and similarity measurements for re-ranking the screened ligands. For
a benchmarking of 44 datasets, including 41 targets, the hybrid methods
increase the identification of active compounds, according to the
early (ROCe%) and total (AUC) enrichment metrics of VS, compared to
pure LB and SB methods. Finally, the hybrid approaches are also more
effective in enhancing the chemical diversity of active compounds.
The datasets employed in this work are available in .